Purple Biotech (PPBT) Cash from Financing Activities (2017 - 2026)
Purple Biotech (PPBT) reported Cash from Financing Activities of -$64000.0 for Q1 2026, down 162.14% year-over-year from $103000.0 in Q1 2025, and down 121.55% quarter-over-quarter from $297000.0 in Q4 2025.
Purple Biotech (PPBT) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Purple Biotech (PPBT) has 10 years of Cash from Financing Activities data on file, last reported at -$64000.0 in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$64000.0, down 162.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.2 million (down 6.7% YoY), and the FY2025 annual result was $6.3 million, down 6.51% from the prior year.
- Cash from Financing Activities eased to -$64000.0 in Q1 2026 per PPBT's latest filing, from $297000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $5.6 million in Q3 2025 and troughed at -$64000.0 in Q1 2026.
- A 5-year average of $1.2 million and a median of $366000.0 in 2025 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities jumped 4670.79% in 2023, then sank 162.14% in 2026.
- A 5-year view of Cash from Financing Activities shows it stood at $89000.0 in 2022, then jumped by 4670.79% to $4.2 million in 2023, then slipped by 7.23% to $3.9 million in 2024, then slumped by 92.46% to $297000.0 in 2025, then slumped by 121.55% to -$64000.0 in 2026.
- Business Quant data shows PPBT's Cash from Financing Activities at -$64000.0 in Q1 2026, $297000.0 in Q4 2025, and $5.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 85,464.43 |
| 10 | Purple Biotech | 242.86 Mn | 236.43 Mn | - | -64,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -64,000.00 |
| Mar 31, 2026 | -64,000.00 |
| Dec 31, 2025 | 297,000.00 |
| Dec 31, 2025 | 297,000.00 |
| Sep 30, 2025 | 5.57 Mn |
| Sep 30, 2025 | 5.57 Mn |
| Jun 30, 2025 | 366,000.00 |
| Jun 30, 2025 | 366,000.00 |
| Mar 31, 2025 | 103,000.00 |
| Mar 31, 2025 | 103,000.00 |
| Dec 31, 2024 | 3.94 Mn |
| Dec 31, 2024 | 3.94 Mn |
| Sep 30, 2024 | 2.13 Mn |
| Sep 30, 2024 | 2.13 Mn |
| Jun 30, 2024 | 433,000.00 |
| Jun 30, 2024 | 433,000.00 |
| Mar 31, 2024 | 268,000.00 |
| Mar 31, 2024 | 268,000.00 |
| Dec 31, 2023 | 4.25 Mn |
| Dec 31, 2023 | 4.25 Mn |